Efgartigimod: a breakthrough medicine for myasthenia gravis

Abstract

Myasthenia gravis (MG) is an autoimmune disease of the neuromuscular junction origin that causes persistent fatigue and weakening of voluntary muscles. MG is the most prevalent neuromuscular junction disorder, with an estimated 150-200 new cases per million individuals per year. Patients with MG presently lack a specific and effective long-term therapeutic option. Patients with generalized MG who test positive for anti-acetylcholine receptor antibodies have demonstrated a positive response to Efgartigimod therapy. Thus, the clinical trial of Efgartigimod for the treatment of generalized MG is a significant step toward the availability of an internationally licensed medicine for the ailment.